ERBB2 and breast cancer: HR+/HER2- breast cancer were historically considered to have a relatively favorable prognosis, whereas HR+/HER2+ subtype seemed to have the best prognosis and HR+/HER2- and HR−/HER2+ subtype had similar survival among patients with de novo metastatic breast cancer in the HER2-targeted therapy era [49, 50].